Antiplatelet therapy in critical limb ischemia: Update on Clopidogrel and cilostazol

Journal of Cardiovascular Surgery

Volumn 55, Issue 5, 2014, Pages 631-640

  Spiliopoulos, S ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Clopidogrel; Ischemia; Platelet aggregation inhibitors

Indexed keywords

CILOSTAZOL; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; TETRAZOLE DERIVATIVE; TICLOPIDINE;

ANTICOAGULANT THERAPY; ARTICLE; CRITICAL LIMB ISCHEMIA; DRUG USE; ENDOVASCULAR SURGERY; HUMAN; MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; CRITICAL ILLNESS; DRUG COMBINATION; ISCHEMIA; LEG; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; RISK FACTOR; STENT; TREATMENT OUTCOME; VASCULARIZATION;

COMBINED MODALITY THERAPY; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; ENDOVASCULAR PROCEDURES; HUMANS; ISCHEMIA; LOWER EXTREMITY; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STENTS; TETRAZOLES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84925232347     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. NICE clinical guideline. CG147 Lower limb peripheral arterial disease. Available from: http://guidance.nice.org.uk/CGl47
2. Comerota AJ. The case for early detection and integrated intervention in patients with peripheral arterial disease and intermittent claudication. J Endovasc Ther 2003;10:601-13.
3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.
4. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, Travison TG, Brookmeyer R. Estimating the prevalence of limb loss in the United States: 2005 to 2050. Arch Phys Med Rehabil 2008;89:422-9.
5. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
6. Norgren L, Hiatt WR, Dormandy JA. TASC II Working Group (2007) Inter-society consensus for the management of peripheral arterial disease (TASCID. Eur J Vase Endovasc Surg 2007;33(Suppl. 1):S1-S75.
7. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss L et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013; 61:1555-70.
8. Altenburg A, Haage P. Antiplatelet and anticoagulant drugs in interventional radiology. Cardiovasc Intervent Radiol 2012;35:30-42.
9. Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004;164:440-6.
10. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012;99:1630-8.
11. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000;60:347-77.
12. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-72.
13. The Caprie Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie). Lancet 1996;348:1329-39.
14. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196-207.
15. European Stroke Organisation l, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: The task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ECS). Eur Heart J 2011;32:2851-906.
16. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
17. NICE. Clopidogrel and modified release dipyridamole in the prevention of occlusive vascular events. NICE technology appraisal guidance 210 (2010). [cited 2014 June 4]. Available from: htpp://www.nice.org.uk/guidance/TA210
18. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the charisma trial. J Am Coll Cardiol 2007;49:1982-8.
19. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the charisma trial. Eur Heart J 2009;30:192-201.
20. Dick F, Ricco JB, Davies AH, Cao P, Setacci C, de Donato G et al. Chapter VI: follow-up after revascularisation. Eur J Vase Endovasc Surg 2011;42(Suppl 2):S75-90.
21. Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Spiliopoulos S, Kagadis GC et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vase Interv Radiol 2009;20:1141-50.
22. Karnabatidis D, Spiliopoulos S, Diamantopoulos A, Katsanos K, Kagadis GC, Kakkos S et al. Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia. J Endovasc Ther 2011;18:1-12.
23. Rastan A, Tepe G, Krankenberg H, Zahorsky R, Beschorner U, Noory E et al. Sirolimus-eluting stents vs. Bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J 2011;32:2274-81.
24. Falkowski A, Poncyljusz W, Wilk G, Szczerbo-Trojanowska M. The evaluation of primary stenting of sirolimus-eluting versus bare-metal stents in the treatment of atherosclerotic lesions of crural arteries. Eur Radiol 2009;19:966-74.
25. Rastan A, Brechtel K, Krankenberg H, Zahorsky R, Tepe G, Noory E et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to baremetal stents: long-term results from a randomized trial. J Am Coll Cardiol 2012;60:587-91.
26. Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, Bosiers M et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol 2012;60:2290-5.
27. Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vase Surg 2012;55:390-8.
28. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61:2417-27.
29. Katsanos Kl, Tepe G, Tsetis D, Fanelli F. Standards of practice for superficial femoral and popliteal artery angioplasty and stenting. Cardiovasc Intervent Radiol 2014;37:592-603.
30. van Overhagen H, Spiliopoulos S, Tsetis D. Below-the-knee interventions. Cardiovasc Intervent Radiol 2013;36:302-11.
31. Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2012;8:CD002071.
32. Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy - the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 2012;22:1998-2006.
33. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R et al. for the Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56:919-33.
34. Spiliopoulos S, Kassimis G, Hatzidakis A, Krokidis M. High on-treatment platelet reactivity in peripheral endovascular procedures. Cardiovasc Intervent Radiol 2014;37:559-71.
35. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013;382:614-23.
36. Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-54.
37. Pastromas G, Spiliopoulos S, Katsanos K, Diamantopoulos A, Kitrou P, Karnabatidis D et al. Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Intervent Radiol 2013;30:1493-9.
38. Elsayed S, Shavelle DM, Matthews RV, Clavijo LC. "Resistance" or high on-treatment platelet reactivity to aspirin and clopidogrel in patients with critical limb ischemia. J Am Coll Cardiol 2012;59:1142-9.
39. Karnabatidis D, Spiliopoulos S, Pastromas G, Kitrou P, Christeas N, Katsanos K et al. Prevalence of non-responsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing. Cardiovasc Intervent Radiol 2014;37:631-8.
40. Kliger C, Babaev A, Shah B. Dual antiplatelet therapy responsiveness in patients undergoing percutaneous revascularization for peripheral arterial occlusive disease. ACC 2012, Chicago, IL, March 24-27.
41. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet responsiveness to clopidogrel treatment after Peripheral endovascular procedures- The PRECLOP study: clinical impact and optimal cut-off value of high on treatment platelet reactivity. J Am Coll Cardiol 2013;61:2428-34.
42. Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat ML. Biotlogical responses in stented arteries. Cardiovasc Res 2013;99:353-63.
43. Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19-2 genotyping. JACC Cardiovasc Interv 2011;4:403-10.
44. Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P et al. Antiplatelet effects of prasugrel vs. Double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost 2011;9:2379-85.
45. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA et al. A pharmacodynamic comparison of prasugrel vs. High-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011;32:838-46.
46. Spiliopoulos S, Katsanos K, Pastromas G, Diamantopoulos A, Kitrou P, Siablis D et al. Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures. Cardiovasc Intervent Radiol 2014 [Epub ahead of print).
47. Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology 2013;124:252-8.
48. Patel MR, Becker RC, Wojdyla DM, Emanuelsson H\ Hiatt WR?, Horrow J et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur J Prev Cardiol 2014 [Epub ahead of print].
49. DiNicolantonio JJ, D'Ascenzo F, Tomek A, Chatterjee S, Niazi AK, Biondi-Zoccai G. Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. Int J Cardiol 2013;168:1739-44.
50. FDA ticagrelor review of complete response - drug approval package. Http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022433Origls000TOC.cfm In: Administration UFaD, editor. Silver Spring, MD: US Department of Health and Human Services; 2011.
51. Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 2012;5:281-9.
52. NICE TA223 (May 2011). Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease, [cited 2014 June 4]. Available from: http://guidance.nice.org. uk/
53. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S et al. Systematic review of the efficacy of ciiostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012;99:1630-8.
54. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005;46:1833-7.
55. Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008;29:2202-11.
56. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005; 6:3-11.
57. Miyashita Y, Saito S, Miyamoto A, Iida O, Nanto S. Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology 2011;62:15e7.
58. Lee TM, Su SF, Tsai CH, Lee YT, Wang SS. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clin Sci (Lond) 2001;101:305-11.
59. Carson SN, Overall K. Adjunctive therapy for ischemic wounds using cilostazol. Wounds 2003;15:77-82.
60. Douglas JS Jr, Holmes DRJr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM etal, for the Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826-32.
61. Lee SW, Park SW, Kim YH. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011;57:1264-70.
62. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus: the DECLARE-DIABETES trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008;51:1181-7.
63. Iida O, Nanto S, Mematsu M, MorozumiT, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vase Surg 2008;48:144e9.
64. Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009;53:48-53.
65. Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013;127:2307-15.
66. Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. Eur J Vase Endovasc Surg 2012;44:577-81.
67. Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study. J Am Coll Cardiol 2009;53:1101-9.
68. Lee BK, Lee SW, Park SW, Lee SW, Park DW, Kim YH et al. Effects of triple antiplatelet therapy with aspirin, clopidogrel and cilostazol on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 2007;100:610-4.
69. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005;46:1833-7.
70. Nakagawa I, Wada T, Park HS, Nishimura F, Yamada S, Nakagawa H et al. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis. J Vase Surg 2014;59:761-7.
71. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C et al.; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9.
72. Range G, Yayehd K, Belle L, Thuaire C, Richard P, Cazaux P et al. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: Verify Now French Registry (VERIFRENCHY). Arch Cardiovasc Dis 2014;107:225-35.